Recent Updates
Recently added Catalysts
VERU Negative Sentiment Score: 20/100

Veru Inc. Sued By Block & Leviton LLP for Securities Law Violations

Key Takeaway: Block & Leviton LLP has filed a class action lawsuit against Veru Inc. and certain executives for alleged securities law violations. The lawsuit, filed in the Southern District of Florida, claims that Veru misled investors regarding the efficacy data for its COVID-19 drug, VERU-111, during the period when its stock price saw a significant decline. The complaint specifically addresses misleading statements made by the company about the support for Emergency Use Authorization. Affected investors who bought shares between May 11, 2022, and November 9, 2022, are encouraged to seek legal counsel.

Market Sentiment Analysis

CONCERNS & RISKS

  • Veru Inc. faces a class action lawsuit for securities fraud.
  • Stock price plunged over 54% after FDA committee voted against EUA.
  • Claims of misleading statements regarding Phase 3 trial data and FDA interaction.
  • Investors who purchased shares during a specific timeframe incurred losses.

Full Press Release Details

BOSTON, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Veru Inc. (NASDAQ: VERU) and certain of its executives, for securities fraud. The complaint was brought in United States District Court for the Southern District of Florida and is captioned Ewing v. Veru Inc., et al., No. 1:22-cv-23960, and is brought on behalf of investors that incurred damages on their purchases in Veru Inc. common stock between May 11, 2022 to November 9, 2022, inclusive.
A class has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Investors who purchased Veru shares between May 11, 2022 and November 9, 2022 and who lost money are strongly encouraged to contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockleviton.com, or to visit our website for information on the case.
The deadline to seek appointment as lead plaintiff is February 6, 2023.
What is this all about?
On November 10, 2022, Veru. Inc.'s stock price plunged by over 54% in mid-morning trading after a Food and Drug Administration Advisory Committee voted against recommending Emergency Use Authorization for the Company's COVID-19 pill VERU-111. The case alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the data from the VERU-111 Phase 3 trial and the Company's interactions with the FDA. Specifically, Veru misled its shareholders to believe that the data from the Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application ("NDA") without any further studies. VERU's filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
If you purchased or acquired Veru shares between May 11, 2022 and November 9, 2022 and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockleviton.com, or visit our website. The deadline to seek appointment as lead plaintiff is February 6, 2023.
Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.
This notice may constitute attorney advertising.
260 Franklin St., Suite 1860
Phone: (617) 398-5600
SOURCE: Block & Leviton LLP

Tags

Frequently Asked Questions

What is the lawsuit against Veru Inc. about?

The lawsuit alleges securities fraud by Veru Inc. and its executives regarding misleading statements about the COVID-19 pill VERU-111.

Who is eligible to join the class action lawsuit?

Investors who bought Veru shares between May 11, 2022, and November 9, 2022, and suffered losses are eligible.

What caused Veru's stock price to drop?

Veru's stock price dropped over 54% after an FDA Advisory Committee voted against recommending Emergency Use Authorization for VERU-111.

What is the deadline to seek lead plaintiff status?

The deadline to seek lead plaintiff status in the lawsuit is February 6, 2023.

How can investors get more information about the case?

Investors can contact Block & Leviton attorneys at (617) 398-5600 or email cases@blockleviton.com for more information.

Last updated: Jan 10, 2023